Salmon Calcitonin in the Treatment of Hypercalcemia

doi:10.1001/archinte.1973.03650090019004

You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.

Vol. 132 No. 3, September 1973

Online Only
	•	Online First Table of Contents

ARTICLES

•	Online Features

This Article
•	References
•	Full text PDF
•	Reply to article
•	Send to a friend
•	Save in My Folder
•	Save to citation manager
•	Permissions

Citing Articles
•	Citation map
•	Citing articles on HighWire
•	Citing articles on Web of Science (85)
•	Contact me when this article is cited

Related Content
•	Similar articles in this journal

Social Bookmarking
	What's this?

Salmon Calcitonin in the Treatment of Hypercalcemia

Omega L. Silva, MD; Kenneth L. Becker, MD, PhD

Arch Intern Med. 1973;132(3):337-339.

Abstract

Synthetic salmon calcitonin was evaluated in 23 patients withhypercalcemia of different causes treated continuously or intermittentlyfor periods from one day to two months. Clinically importantdecreases in serum calcium level were achieved in 17. The responsewas only partial; often the serum calcium descended from dangerouslyhigh levels to a tolerable range or to minimal hypercalcemia.The drug was nontoxic, and hypersensitivity did not occur, inspite of recommencement of therapy after days or weeks of cessation.Salmon calcitonin was found to be particularly useful as aninitial emergency drug for hypercalcemic patients with heartfailure or azotemia or both. It often facilitated the clinicalimprovement that was necessary for these patients to toleratemore definitive therapy or other hypocalcemic agents.

Author Affiliations

Washington, DC

From the Veterans Administration Hospital and George Washington University, Washington, DC.

Footnotes

Received for publication April 12, 1972; accepted Feb 9, 1973.

Reprint requests to 50 Irving St NW, Washington, DC 20422 (Dr.Silva).

Add to CiteULike CiteULike Add to Connotea Connotea Add to Delicious Delicious Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Calcitonin Receptor Regulation and Responsiveness to Calcitonin in Human Osteoclast-Like Cells Prepared in Vitro using Receptor Activator of Nuclear Factor-{kappa}B Ligand and Macrophage Colony-Stimulating Factor
Samura et al.
Endocrinology 2000;141:3774-3782.
ABSTRACT | FULL TEXT

Calcitonin-Dependent Down-Regulation of the Mouse C1a Calcitonin Receptor in Cells of the Osteoclast Lineage Involves a Transcriptional Mechanism
Inoue et al.
Endocrinology 1999;140:1060-1068.
ABSTRACT | FULL TEXT

Regulation by Calcitonin and Glucocorticoids of Calcitonin Receptor Gene Expression in Mouse Osteoclasts
Wada et al.
Endocrinology 1997;138:521-529.
ABSTRACT | FULL TEXT

Fast and Effective Treatment of Malignant Hypercalcemia: Combination of Suppositories of Calcitonin and a Single Infusion of 3-Amino 1-Hydroxypropylidene-1-bisphosphonate
Thiebaud et al.
Arch Intern Med 1990;150:2125-2128.
ABSTRACT

Gallium Nitrate for Acute Treatment of Cancer-Related Hypercalcemia: A Randomized, Double-Blind Comparison to Calcitonin
WARRELL et al.
ANN INTERN MED 1988;108:669-674.
ABSTRACT

Drugs Five Years Later: Calcitonin as a Drug
DEFTOS and FIRST
ANN INTERN MED 1981;95:192-197.
ABSTRACT

Combined Calcitonin and Oral Phosphate Treatment for Hypercalcemia in Multiple Myeloma
Brautbar and Luboshitzky
Arch Intern Med 1977;137:914-916.
ABSTRACT

Calcitonin Treatment of Hypercalcemia Due to Parathyroid Carcinoma: Synergistic Effect of Prednisone on Long-Term Treatment of Hypercalcemia
Au
Arch Intern Med 1975;135:1594-1597.
ABSTRACT

| | |